Benzinga's options scanner just detected over 16 options trades for Moderna (NASDAQ:MRNA) summing a total amount of $1,134,726. At the same time, our algo caught 10 for a total amount of 1,113,875.

Looking at options history for Moderna (NASDAQ:MRNA) we detected 26 trades. If we consider the specifics of each trade, it is accurate to state that 46% of the investors opened trades with bullish ...

Moderna (NASDAQ:MRNA) stock drops ~5% as its Q4 2024 results show revenue beat but earnings miss expectations. Read more here ...

Despite a significant revenue decline, Moderna Inc (MRNA) focuses on strategic program prioritization and cost management to ...

Moderna (MRNA) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives ...

We expect Moderna MRNA to surpass expectations when it reports fourth-quarter and full-year 2024 earnings on Feb. 14, before the opening bell. In the last reported quarter, MRNA’s earnings beat ...

MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...

Wilmington Savings Fund Society FSB grew its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 295.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 786 shares of the ...

Valued at $13.1 billion by market cap, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) operates as a clinical-stage pharmaceutical company. It focuses on discovering and developing messenger ...

Moderna is a victim of its own success ... views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom ...

Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The biotech, renowned for its pioneering development of vaccines based on ...

In contrast to shares of AbbVie and Gilead Sciences, which have been strong performers to kick off 2025, Moderna (NASDAQ: MRNA) stands out as a turnaround opportunity. The company, recognized for ...